Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on April 30, 2009, covering events occurring on April 29, 2009. The company is a Delaware corporation focused on the development of its rPA anthrax vaccine, SparVaxTM.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a disclosure of a regulatory event rather than a financial statement.
Material Changes and Events
- Regulation FD Disclosure: The company hosted an investor conference call on April 29, 2009, to discuss the status of the SparVaxTM program.
- Funding and Bids: The call addressed existing funding for the vaccine program and the status of a bid submitted under the DHHS Request for Proposal (RFP-BARDA-08-15) for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile.
Guidance, Outlook, and Risks
The filing references a transcript of the investor conference call (Exhibit 99.1) for detailed information regarding the program's outlook. The company explicitly states that the information in this report is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. Investors are directed to the Form 10-K for the year ended December 31, 2008, for more detailed historical information.
Investor Verification Checklist
- Verify the outcome of the DHHS RFP-BARDA-08-15 bid for the Strategic National Stockpile.
- Review the attached Exhibit 99.1 (Conference Call Transcript) for specific details on funding levels and program milestones.
- Consult the Form 10-K for the fiscal year ended December 31, 2008, for audited financial data and comprehensive risk factors.
- Confirm the current cash runway and burn rate, as these are not disclosed in this specific 8-K filing.